Published in Sci Transl Med on February 29, 2012
Infectious disease. Combating emerging viral threats. Science (2015) 2.19
Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother (2014) 1.66
Emerging targets and novel approaches to Ebola virus prophylaxis and treatment. BioDrugs (2013) 1.57
Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs. Emerg Microbes Infect (2014) 1.18
The Ebola virus matrix protein penetrates into the plasma membrane: a key step in viral protein 40 (VP40) oligomerization and viral egress. J Biol Chem (2013) 1.07
Small-molecule probes targeting the viral PPxY-host Nedd4 interface block egress of a broad range of RNA viruses. J Virol (2014) 0.99
New tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeutics. Immunol Rev (2015) 0.90
The Ebola virus matrix protein VP40 selectively induces vesiculation from phosphatidylserine-enriched membranes. J Biol Chem (2014) 0.86
Multifunctional Abl kinases in health and disease. J Cell Sci (2016) 0.83
The multifunctional Ebola virus VP40 matrix protein is a promising therapeutic target. Future Virol (2015) 0.81
A loop region in the N-terminal domain of Ebola virus VP40 is important in viral assembly, budding, and egress. Viruses (2014) 0.81
Immunological off-target effects of imatinib. Nat Rev Clin Oncol (2016) 0.81
A human genome-wide loss-of-function screen identifies effective chikungunya antiviral drugs. Nat Commun (2016) 0.80
Low doses of imatinib induce myelopoiesis and enhance host anti-microbial immunity. PLoS Pathog (2015) 0.80
Predictive and comparative analysis of Ebolavirus proteins. Cell Cycle (2015) 0.79
ITCH E3 Ubiquitin Ligase Interacts with Ebola Virus VP40 To Regulate Budding. J Virol (2016) 0.78
Hepatitis C Virus Particle Assembly Involves Phosphorylation of NS5A by the c-Abl Tyrosine Kinase. J Biol Chem (2015) 0.78
Calcium Regulation of Hemorrhagic Fever Virus Budding: Mechanistic Implications for Host-Oriented Therapeutic Intervention. PLoS Pathog (2015) 0.78
Ebola VP40 in Exosomes Can Cause Immune Cell Dysfunction. Front Microbiol (2016) 0.77
Possible FDA-approved drugs to treat Ebola virus infection. Infect Dis Poverty (2015) 0.77
Phosphorylation of Single Stranded RNA Virus Proteins and Potential for Novel Therapeutic Strategies. Viruses (2015) 0.76
The Lymphocytic Choriomeningitis Virus Matrix Protein PPXY Late Domain Drives the Production of Defective Interfering Particles. PLoS Pathog (2016) 0.76
Evaluation of the Activity of Lamivudine and Zidovudine against Ebola Virus. PLoS One (2016) 0.76
Antiviral Screening of Multiple Compounds against Ebola Virus. Viruses (2016) 0.75
Synergistic drug combination effectively blocks Ebola virus infection. Antiviral Res (2016) 0.75
Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion. J Virol (2016) 0.75
Single nucleoprotein residue modulates arenavirus replication complex formation. MBio (2015) 0.75
Identification and characterization of the role of c-terminal Src kinase in dengue virus replication. Sci Rep (2016) 0.75
Ubiquitin Ligase WWP1 Interacts with Ebola Virus VP40 to Regulate Egress. J Virol (2017) 0.75
Abl Tyrosine Kinase Regulates Hepatitis C Virus Entry. Front Microbiol (2017) 0.75
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med (2006) 9.07
Chronic myeloid leukemia. N Engl J Med (1999) 7.11
A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: implications for filovirus budding. Proc Natl Acad Sci U S A (2000) 5.30
Translation of the Philadelphia chromosome into therapy for CML. Blood (2008) 4.74
Molecular dynamics and protein function. Proc Natl Acad Sci U S A (2005) 4.70
Mass spectrometric identification of proteins from silver-stained polyacrylamide gel: a method for the removal of silver ions to enhance sensitivity. Electrophoresis (1999) 3.71
Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J Virol (2002) 3.62
Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis. Nature (1999) 3.50
Reprogramming control of an allosteric signaling switch through modular recombination. Science (2003) 3.15
pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J Virol (2004) 3.04
Contribution of ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles. J Virol (2004) 2.92
The assembly of Ebola virus nucleocapsid requires virion-associated proteins 35 and 24 and posttranslational modification of nucleoprotein. Mol Cell (2002) 2.80
Mitogen-activated protein kinases: versatile transducers for cell signaling. Trends Biochem Sci (1992) 2.80
Descriptive analysis of Ebola virus proteins. Virology (1985) 2.65
Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat Med (2005) 2.43
AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer (2006) 2.33
Nedd4 regulates egress of Ebola virus-like particles from host cells. J Virol (2003) 2.19
Ebola virus matrix protein VP40 interaction with human cellular factors Tsg101 and Nedd4. J Mol Biol (2003) 2.11
Ebola virus protein VP35 impairs the function of interferon regulatory factor-activating kinases IKKepsilon and TBK-1. J Virol (2009) 2.10
Ebola virus VP40 late domains are not essential for viral replication in cell culture. J Virol (2005) 1.97
Context-dependent effects of L domains and ubiquitination on viral budding. J Virol (2004) 1.92
Rewiring cell signaling: the logic and plasticity of eukaryotic protein circuitry. Curr Opin Struct Biol (2004) 1.83
Protective immunity to lethal challenge of the 1918 pandemic influenza virus by vaccination. Proc Natl Acad Sci U S A (2006) 1.83
Grb2 and Nck act cooperatively to promote actin-based motility of vaccinia virus. Curr Biol (2002) 1.71
Assembly and budding of Ebolavirus. PLoS Pathog (2006) 1.62
Chronic myeloid leukemia: current treatment options. Blood (2001) 1.62
AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res (2005) 1.61
Effect of Ebola virus proteins GP, NP and VP35 on VP40 VLP morphology. Virol J (2006) 1.60
Abl tyrosine kinases are required for infection by Shigella flexneri. EMBO J (2003) 1.59
Filovirus assembly and budding. Virology (2006) 1.56
Filoviruses: Interactions with the host cell. Cell Mol Life Sci (2008) 1.48
Immunopathology of highly virulent pathogens: insights from Ebola virus. Nat Immunol (2007) 1.45
Oligomerization of Ebola virus VP40 is essential for particle morphogenesis and regulation of viral transcription. J Virol (2010) 1.39
Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia (2009) 1.34
Enteropathogenic Escherichia coli use redundant tyrosine kinases to form actin pedestals. Mol Biol Cell (2004) 1.32
Abl collaborates with Src family kinases to stimulate actin-based motility of vaccinia virus. Cell Microbiol (2006) 1.30
Role of Ebola virus VP30 in transcription reinitiation. J Virol (2008) 1.28
AMN107: tightening the grip of imatinib. Cancer Cell (2005) 1.27
Cardiotoxicity associated with targeting kinase pathways in cancer. Toxicol Sci (2010) 1.26
Phosphorylation of Marburg virus VP30 at serines 40 and 42 is critical for its interaction with NP inclusions. Virology (2001) 1.22
Filovirus budding. Virus Res (2004) 1.21
Association of ebola virus matrix protein VP40 with microtubules. J Virol (2005) 1.18
Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. Blood (2004) 1.17
The nucleoprotein of Marburg virus is phosphorylated. J Gen Virol (1994) 1.17
Development of a broad-spectrum antiviral with activity against Ebola virus. Antiviral Res (2009) 1.06
Conserved motifs within Ebola and Marburg virus VP40 proteins are important for stability, localization, and subsequent budding of virus-like particles. J Virol (2009) 1.06
Enteropathogenic Escherichia coli Tir is an SH2/3 ligand that recruits and activates tyrosine kinases required for pedestal formation. Mol Microbiol (2007) 1.06
Variola and monkeypox viruses utilize conserved mechanisms of virion motility and release that depend on abl and SRC family tyrosine kinases. J Virol (2010) 1.02
A filovirus-unique region of Ebola virus nucleoprotein confers aberrant migration and mediates its incorporation into virions. J Virol (2008) 1.01
Viral and host proteins that modulate filovirus budding. Future Virol (2010) 0.93
FGI-104: a broad-spectrum small molecule inhibitor of viral infection. Am J Transl Res (2009) 0.91
Abl: mechanisms of regulation and activation. Front Biosci (2002) 0.91
The Marburg virus surface protein GP is phosphorylated at its ectodomain. Virology (2002) 0.89
Abl family tyrosine kinases regulate sialylated ganglioside receptors for polyomavirus. J Virol (2010) 0.88
Influence of calcium/calmodulin on budding of Ebola VLPs: implications for the involvement of the Ras/Raf/MEK/ERK pathway. Virus Genes (2007) 0.82
Uncommon or delayed adverse events associated with imatinib treatment for chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk (2010) 0.80
Overview of second-generation tyrosine kinase inhibitors for patients with imatinib-resistant chronic myelogenous leukemia. Clin J Oncol Nurs (2007) 0.78
Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science (2010) 14.91
Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature (2007) 11.73
Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science (2010) 10.69
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics (2013) 9.98
HIV vaccine design and the neutralizing antibody problem. Nat Immunol (2004) 9.48
voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol (2014) 8.13
Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science (2011) 7.92
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature (2011) 7.20
Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA (2002) 6.59
Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature (2003) 6.35
Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science (2006) 6.06
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis (2006) 5.53
Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell (2003) 5.44
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest (2007) 5.17
Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science (2010) 5.13
Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity (2013) 4.82
Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med (2009) 4.79
Medicine. The need for a global HIV vaccine enterprise. Science (2003) 4.70
Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat Med (2011) 4.68
The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote. Nucleic Acids Res (2013) 4.45
Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol (2004) 4.36
Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science (2009) 4.20
Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol (2011) 4.06
Rac and Cdc42 play distinct roles in regulating PI(3,4,5)P3 and polarity during neutrophil chemotaxis. J Cell Biol (2003) 4.02
A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature (2004) 3.90
The transcription factors Blimp-1 and IRF4 jointly control the differentiation and function of effector regulatory T cells. Nat Immunol (2011) 3.44
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis (2006) 3.40
A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology (2006) 3.26
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med (2013) 3.24
DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis (2011) 3.19
DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell (2005) 3.12
Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys. Sci Transl Med (2011) 3.08
A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging. Eur J Nucl Med Mol Imaging (2004) 3.07
Cross-neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design. Sci Transl Med (2010) 3.06
pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J Virol (2004) 3.04
A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis (2007) 3.02
Immunization by avian H5 influenza hemagglutinin mutants with altered receptor binding specificity. Science (2007) 2.95
Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. J Virol (2002) 2.89
Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med (2004) 2.89
MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest (2010) 2.87
Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol (2002) 2.83
Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine (2005) 2.82
The assembly of Ebola virus nucleocapsid requires virion-associated proteins 35 and 24 and posttranslational modification of nucleoprotein. Mol Cell (2002) 2.80
Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest (2009) 2.80
Comprehensive MicroRNA profiling for head and neck squamous cell carcinomas. Clin Cancer Res (2010) 2.79
Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol (2009) 2.71
Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine (2007) 2.68
Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol (2003) 2.67
Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med (2006) 2.64
Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys. J Virol (2004) 2.63
The gene product Murr1 restricts HIV-1 replication in resting CD4+ lymphocytes. Nature (2003) 2.63
A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat Med (2010) 2.62
Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J Virol (2005) 2.61
Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge. J Exp Med (2006) 2.60
The transcription factor IRF4 is essential for TCR affinity-mediated metabolic programming and clonal expansion of T cells. Nat Immunol (2013) 2.48
Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med (2014) 2.47
A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J Virol (2005) 2.44
Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat Med (2005) 2.43
Antigen-specific transforming growth factor β-induced Treg cells, but not natural Treg cells, ameliorate autoimmune arthritis in mice by shifting the Th17/Treg cell balance from Th17 predominance to Treg cell predominance. Arthritis Rheum (2012) 2.43
Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues. Lab Invest (2009) 2.43
Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat Struct Mol Biol (2013) 2.42
Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J Virol (2005) 2.40
A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol (2006) 2.39
Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum Gene Ther (2005) 2.32
Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res (2007) 2.32
Lung organogenesis. Curr Top Dev Biol (2010) 2.30
Design and synthesis of 3d-4f metal-based zeolite-type materials with a 3D nanotubular structure encapsulated "water" pipe. J Am Chem Soc (2004) 2.30
TLR signaling mediated by MyD88 is required for a protective innate immune response by neutrophils to Citrobacter rodentium. J Immunol (2007) 2.27
Ebola virus pathogenesis: implications for vaccines and therapies. J Virol (2003) 2.25
Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS One (2010) 2.24
Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. Nat Rev Immunol (2013) 2.22
Role of SMAD and non-SMAD signals in the development of Th17 and regulatory T cells. J Immunol (2010) 2.20
Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity (2013) 2.17
Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res (2008) 2.17
MiR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Res (2011) 2.15
Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus. J Virol (2008) 2.14
Synthesis, crystal structure, magnetic properties and theoretical studies on a one-dimensional polynuclear copper(II) complex [Cu2(mu1,3-SCN)2(mu'1,3-SCN)2(MPyO)2]n. Dalton Trans (2005) 2.12
The rational design of an AIDS vaccine. Cell (2006) 2.11
Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines. J Virol (2003) 2.09
Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature (2013) 2.08
Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site. PLoS Pathog (2009) 2.07
PI3 kinase enhancer-Homer complex couples mGluRI to PI3 kinase, preventing neuronal apoptosis. Nat Neurosci (2003) 2.06
Heterochromatin, HP1 and methylation at lysine 9 of histone H3 in animals. Chromosoma (2002) 2.03
Relationship between syphilis and HIV infections among men who have sex with men in Beijing, China. Sex Transm Dis (2007) 2.00
Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med (2015) 1.99
Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs. Vaccine (2006) 1.99
A growth factor-dependent nuclear kinase phosphorylates p27(Kip1) and regulates cell cycle progression. EMBO J (2002) 1.99
Heterochromatin and tri-methylated lysine 20 of histone H4 in animals. J Cell Sci (2004) 1.98
Visual and anatomical outcomes of macular epiretinal membrane peeling after previous rhegmatogenous retinal detachment repair. Retina (2015) 1.98
Molecular mechanisms of early lung specification and branching morphogenesis. Pediatr Res (2005) 1.97
Structural and genetic basis for development of broadly neutralizing influenza antibodies. Nature (2012) 1.93
A novel role for XIAP in copper homeostasis through regulation of MURR1. EMBO J (2003) 1.90
Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res (2007) 1.90
Infection of specific dendritic cells by CCR5-tropic human immunodeficiency virus type 1 promotes cell-mediated transmission of virus resistant to broadly neutralizing antibodies. J Virol (2004) 1.89
Outcomes of sulfur hexafluoride (SF6) versus perfluoropropane (C3F8) gas tamponade for macular hole surgery. Retina (2008) 1.89
No evidence for consistent virus-specific immunity in simian immunodeficiency virus-exposed, uninfected rhesus monkeys. J Virol (2007) 1.89